입자선 치료(Particle Therapy) 시장 : 2027년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년05월

입자선 치료(Particle Therapy) 시장 : 유형(양자선 치료, 중립자 치료), 제품(사이클로트론, 싱크로트론, 싱크로사이클로트론), 서비스, 시스템(싱글룸, 멀티룸), 암의 유형(소아, 전립선), 용도(치료, 연구)- 2027년까지의 세계 예측

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) – Global Forecast to 2027

페이지수 203
도표수 214
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

MarketsandMarkets expects particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027. Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide. However, affordability & accessibility of treatments and infrastructural are expected to limit market growth to a certain extent in the coming years.
MarketsandMarkets는 입자 치료 시장이 2022년 6억 7,700만 달러에서 2027년까지 10억 4,000만 달러에 이를 것으로 예상하고 있으며, 2022년부터 2027년까지 8.2%의 CAGR로 성장할 것으로 예상합니다. 암의 증가, 광자 치료에 비해 입자 치료의 이점, 임상 시험에서 입자 치료의 수용 증가, 전 세계적으로 입자 치료 센터의 증가하는 수. 그러나 치료 및 인프라의 경제성 및 접근성은 향후 몇 년 동안 시장 성장을 어느 정도 제한할 것으로 예상됩니다.

In this report, the particle therapy market is segmented on the basis of type, product and services, cancer type, application, cancer type, and region.
“Treatment Application accounted for the largest share in the particle therpy market by application type”
Based on applications, the particle therapy market has been segmented into treatment and research applications. In 2021, the treatment applications segment is projected to account for the dominant share of 94.4% of the particle therapy market. Increasing government initiatives aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems.

“Proton Therapy accounted for the largest share in the particle therpy market by type”

On the basis of type, the particle therapy market is segmented into proton therapy and heavy ion therapy. The proton therapy segment is expected to account for the largest share (85.7%) of the market in 2021. Factors such as the high dose of radiation, shorter treatment time, a high degree of precision, and lowered side effects as compared to conventional photon therapies using traditional X-rays.

“Based on product, cyclotrons accounted for the largest share in the particle therpy market”

Based on product, the particle therapy products market is further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. In 2021, the cyclotrons segment is expected to account for a share of 71.4% of the particle therapy market; this segment is projected to grow at a CAGR of 6.7% during the forecast period. Advantages offered by cyclotrons over other accelerators and the development of technologically advanced systems are the major factors pushing the development of this market segment.

“Asia Pacific segment accounted for the largest share in the particle therapy market by Region”
The Asia Pacific market is expected to account for the largest market share in 2021 and is also projected to witness the highest growth rate during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the particle therapy market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in the Asia Pacific countries.

Key Market Players :
Prominent players in the particle therapy market include IBA Worldwide (EU), Hitachi, Ltd. (Japan), Varian Medical Systems, Inc. (US), Provision Healthcare, LLC (US), Optivus Proton Therapy, Inc. (US), and Protom International, Inc. (US).
A breakdown of the primary participants (supply-side) for the particle therapy market referred to for this report is provided below:
• By Company Type: Tier 1–5%, Tier 2–15%, and Tier 3–80%
• By Designation: C-level–45%, Director Level–25%, and Others–30%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America- 10%, and Middle East and Africa– 7%


Research Coverage:
The market study covers the particle therapy market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, by application, by end user, and by region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the particle therapy market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 27)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 MARKETS COVERED – BY REGION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 32)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020)
FIGURE 5 SUPPLY SIDE ANALYSIS: PARTICLE THERAPY MARKET
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022– 2027)
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (2021)
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 KEY INDUSTRY INSIGHTS
2.5 LIMITATIONS
2.5.1 METHODOLOGY-RELATED LIMITATIONS
2.6 RISK ASSESSMENT
2.7 STUDY ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. – 45)
FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 PARTICLE THERAPY MARKET, BY PRODUCTS, 2022 VS. 2027 (USD MILLION)
FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEMS, 2022 VS. 2027 (USD MILLION)
FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET

4 PREMIUM INSIGHTS (Page No. – 50)
4.1 PARTICLE THERAPY MARKET OVERVIEW
FIGURE 17 INCREASING CANCER PREVALENCE TO DRIVE MARKET GROWTH
4.2 REGIONAL MIX: PARTICLE THERAPY MARKET
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
4.3 ASIA PACIFIC: PARTICLE THERAPY M ARKET, BY TYPE AND COUNTRY (2021)
FIGURE 19 PROTON THERAPY TO ACCOUNT FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD
4.5 PARTICLE THERAPY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 54)
5.1 INTRODUCTION
TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS
5.1.1 DRIVERS
5.1.1.1 Advantages offered by particle therapy over photon therapy
5.1.1.2 Growing global prevalence of cancer
5.1.1.3 Growing adoption of particle therapy in clinical trials
5.1.1.4 Increasing number of particle therapy centers worldwide
5.1.1.5 Rising technological advancements
5.1.2 RESTRAINTS
5.1.2.1 Infrastructural challenges in healthcare facilities
5.1.2.2 Affordability and accessibility of treatments
5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy
5.1.3 OPPORTUNITIES
5.1.3.1 Growing adoption of particle therapy in emerging markets
5.1.3.2 Rising healthcare expenditure across developing countries
5.1.4 CHALLENGES
5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures
5.1.4.2 Increasing risk of radiation exposure
5.2 COVID-19 IMPACT ON ECONOMIC SCENARIO IN PARTICLE THERAPY MARKET
5.3 ECOSYSTEM ANALYSIS
FIGURE 22 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS
5.4 PRICING ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 23 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET
FIGURE 24 GLOBAL PATENT PUBLICATION TRENDS IN PARTICLE THERAPY, 2016-2021
5.6.2 TOP APPLICANTS (COMPANIES) FOR PARTICLE THERAPY PATENTS
FIGURE 25 TOP COMPANIES THAT APPLIED FOR PARTICLE THERAPY PRODUCTS PATENTS, 2016–2021
5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PARTICLE THERAPY MARKET
FIGURE 26 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PARTICLE THERAPY PATENTS, 2016–2021
5.7 VALUE CHAIN ANALYSIS
FIGURE 27 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS (2021)
5.8 TECHNOLOGY ANALYSIS
5.9 KEY CONFERENCES & EVENTS IN 2022-2023
5.10 REGULATORY LANDSCAPE
TABLE 3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
TABLE 4 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
FIGURE 28 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
FIGURE 29 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
FIGURE 30 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
FIGURE 31 BARGAINING POWER OF BUYERS
5.11.5 DEGREE OF COMPETITION
FIGURE 32 DEGREE OF COMPETITION
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 6 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS (%)
5.12.2 BUYING CRITERIA
FIGURE 34 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
TABLE 7 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS

6 PARTICLE THERAPY MARKET, BY TYPE (Page No. – 75)
    6.1 INTRODUCTION
TABLE 8 PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 PROTON THERAPY
6.2.1 PROTON THERAPY TO BE INCREASINGLY ADOPTED AS PRIMARY TREATMENT MODE FOR VARIOUS CANCER TYPES
TABLE 9 PARTICLE THERAPY MARKET FOR PROTON THERAPY, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 HEAVY ION THERAPY
6.3.1 USE OF HEAVY ION THERAPY TO BE STILL IN EXPERIMENTAL PHASE ACROSS MANY REGIONS
TABLE 10 PARTICLE THERAPY MARKET FOR HEAVY ION THERAPY, BY COUNTRY, 2020–2027 (USD MILLION)

7 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE (Page No. – 79)
7.1 INTRODUCTION
TABLE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
7.2 PRODUCTS
TABLE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2020–2027(USD MILLION)
TABLE 13 PARTICLE THERAPY PRODUCT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CYCLOTRONS
7.3.1 INCREASED MANUFACTURING BY LEADING PLAYERS IN PARTICLE THERAPY TO PROPEL MARKET GROWTH
TABLE 14 PARTICLE THERAPY CYCLOTRONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 SYNCHROTRONS
7.4.1 INCREASING INVESTMENTS FOR DEVELOPMENT FACILITIES TO AID MARKET GROWTH
TABLE 15 PARTICLE THERAPY SYNCHROTRONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 SYNCHROCYCLOTRON
7.5.1 HIGH SPACE REQUIREMENTS TO LIMIT WIDESPREAD ADAPTION
TABLE 16 PARTICLE THERAPY SYNCHROCYCLOTRON MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 SERVICES
TABLE 17 PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 PARTICLE THERAPY MARKET, BY SYSTEM (Page No. – 86)
    8.1 INTRODUCTION
TABLE 18 PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
8.2 MULTI-ROOM SYSTEMS
8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS
TABLE 19 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 SINGLE-ROOM SYSTEMS
8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COSTS TO PROPEL SEGMENT GROWTH
TABLE 20 PARTICLE THERAPY MARKET FOR SINGLE ROOM SYSTEM, BY COUNTRY, 2020–2027 (USD MILLION)

9 PARTICLE THERAPY MARKET, BY CANCER TYPE (Page No. – 90)
9.1 INTRODUCTION
TABLE 21 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
9.2 PEDIATRIC CANCER
9.2.1 BETTER CONTROL OF RADIATION WITH PARTICLE THERAPY TO POPULARIZE THIS TREATMENT MODE
TABLE 22 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 PROSTATE CANCER
9.3.1 PARTICLE THERAPY TO OFFER MINIMALLY INVASIVE ALTERNATIVE WITH INCREASED ACCURACY
TABLE 23 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 LUNG CANCER
9.4.1 RISING NUMBER OF CLINICAL TRIALS TO OPTIMIZE PARTICLE THERAPY TO DRIVE MARKET GROWTH
TABLE 24 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 BREAST CANCER
9.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY
TABLE 25 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
9.6 HEAD & NECK CANCER
9.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT SEGMENT GROWTH
TABLE 26 PARTICLE THERAPY MARKET FOR HEAD AND NECK CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
9.7 OTHER CANCERS
TABLE 27 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION)

10 PARTICLE THERAPY MARKET, BY APPLICATION (Page No. – 98)
10.1 INTRODUCTION
TABLE 28 PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2 TREATMENT APPLICATIONS
10.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO PROMOTE PARTICLE THERAPY FOR CANCER TREATMENT
TABLE 29 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 RESEARCH APPLICATIONS
10.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES
TABLE 30 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)

11 PARTICLE THERAPY MARKET, BY REGION (Page No. – 102)
11.1 INTRODUCTION
FIGURE 35 CHINA TO DOMINATE PARTICLE THERAPY MARKET DURING FORECAST PERIOD
TABLE 31 PARTICLE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 PARTICLE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT
TABLE 33 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Growing number of particle therapy centers to drive market growth
TABLE 40 US: MACROECONOMIC INDICATORS
TABLE 41 US: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 42 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 43 US: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 44 US: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 45 US: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 46 US: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Canadian government to initiate inclusion of particle therapy as treatment method
TABLE 47 CANADA: MACROECONOMIC INDICATORS
TABLE 48 CANADA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 50 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 51 CANADA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 52 CANADA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 53 CANADA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3 EUROPE
FIGURE 37 EUROPE: PARTICLE THERAPY MARKET SNAPSHOT
TABLE 54 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing research in proton and heavy ion therapy to drive market growth
TABLE 61 GERMANY: MACROECONOMIC INDICATORS
TABLE 62 GERMANY: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 64 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 65 GERMANY: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 66 GERMANY: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 67 GERMANY: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Increasing healthcare expenditure to support particle therapy products adoption
TABLE 68 FRANCE: MACROECONOMIC INDICATORS
TABLE 69 FRANCE: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 71 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 72 FRANCE: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 73 FRANCE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 74 FRANCE: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Cyclotrons segment to dominate market growth
TABLE 75 UK: MACROECONOMIC INDICATORS
TABLE 76 UK: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 77 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 78 UK: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 79 UK: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 80 UK: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 81 UK: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing awareness activities to support market growth
TABLE 82 ITALY: MACROECONOMIC INDICATORS
TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 85 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 86 ITALY: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 87 ITALY: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 88 ITALY: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing number of conferences and government funding for cancer research to drive market growth
TABLE 89 SPAIN: MACROECONOMIC INDICATORS
TABLE 90 SPAIN: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 92 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 SPAIN: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 94 SPAIN: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 95 SPAIN: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 96 REST OF EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 98 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 99 REST OF EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 100 REST OF EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 101 REST OF EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 38 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT
TABLE 102 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Increasing use of heavy ion therapy for cancer treatment to propel market growth
TABLE 109 JAPAN: MACROECONOMIC INDICATORS
TABLE 110 JAPAN: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 112 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 113 JAPAN: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 114 JAPAN: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 115 JAPAN: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Growing interest of major market players to increase their presence to drive market growth
TABLE 116 CHINA: MACROECONOMIC INDICATORS
TABLE 117 CHINA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 119 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 120 CHINA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 121 CHINA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 122 CHINA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Leading product manufacturers with high growth opportunities to propel market growth
TABLE 123 INDIA: MACROECONOMIC INDICATORS
TABLE 124 INDIA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 126 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 127 INDIA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 128 INDIA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 129 INDIA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 130 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 132 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 133 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 134 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 135 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LOW-COST SURGERIES TO DRIVE MEDICAL TOURISM
TABLE 136 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 138 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 140 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 141 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH
TABLE 142 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 145 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION)
TABLE 146 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 147 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. – 156)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION QUADRANT
FIGURE 41 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 PERVASIVE PLAYERS
12.5.3 EMERGING LEADERS
12.5.4 PARTICIPANTS
12.6 COMPETITIVE BENCHMARKING
12.6.1 OVERALL COMPANY FOOTPRINT
TABLE 148 OVERALL COMPANY FOOTPRINT (13 COMPANIES)
TABLE 149 COMPANY FOOTPRINT: BY-TYPE (13 COMPANIES)
TABLE 150 COMPANY FOOTPRINT: BY PRODUCT & SERVICES (13 COMPANIES)
TABLE 151 COMPANY FOOTPRINT: BY SYSTEM (13 COMPANIES)
TABLE 152 COMPANY FOOTPRINT: BY CANCER TYPE (13 COMPANIES)
TABLE 153 COMPANY FOOTPRINT: BY APPLICATION (13 COMPANIES)
TABLE 154 COMPANY FOOTPRINT: BY REGION (13 COMPANIES)
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES & APPROVALS
12.7.2 DEALS
TABLE 155 DEALS
12.7.3 EXPANSIONS
TABLE 156 EXPANSIONS

13 COMPANY PROFILES (Page No. – 171)
     13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 IBA WORLDWIDE
TABLE 157 IBA WORLDWIDE: BUSINESS OVERVIEW
FIGURE 42 IBA WORLDWIDE: COMPANY SNAPSHOT (2021)
13.1.2 VARIAN MEDICAL SYSTEMS, INC.
TABLE 158 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 43 VARIAN MEDICAL SYSTEMS, INC: COMPANY SNAPSHOT (2021)
13.1.3 HITACHI LTD.
TABLE 159 HITACHI LTD.: BUSINESS OVERVIEW
FIGURE 44 HITACHI LTD.: COMPANY SNAPSHOT (2020)
13.1.4 MEVION MEDICAL SYSTEMS
TABLE 160 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW
13.1.5 SUMITOMO HEAVY INDUSTRIES LTD.
TABLE 161 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 45 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)
13.1.6 PROVISION HEALTHCARE, LLC
TABLE 162 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION
TABLE 163 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
FIGURE 46 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2020)
13.1.8 OPTIVUS PROTON THERAPY, INC.
TABLE 164 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW
13.1.9 PROTOM INTERNATIONAL, INC.
TABLE 165 PROTOM INTERNATIONAL INC.: BUSINESS OVERVIEW
13.1.10 ADVANCED ONCOTHERAPY PLC.
TABLE 166 ADVANCED ONCOTHERAPY PLC.: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 DANFYSIK A/S
TABLE 167 DANFYSIK A/S.: BUSINESS OVERVIEW
13.2.2 P-CUREA
TABLE 168 P-CURE: BUSINESS OVERVIEW
13.2.3 PTW FREIBURG GMBH

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. – 201)
     14.1 DISCUSSION GUIDE
14.2 INDUSTRY INSIGHTS
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com